3 learning resources available for this topic
Epinephrine is the first-line treatment for anaphylaxis, a severe life-threatening allergic reaction that can cause airway obstruction, cardiovascular collapse, and death within minutes. It must be administered immediately upon recognition of anaphylactic symptoms, as delays in treatment significantly increase morbidity and mortality. Epinephrine works through both alpha and beta-adrenergic receptor activation to counteract the pathophysiological cascade of anaphylaxis.
Anaphylaxis involves massive mast cell and basophil degranulation, releasing inflammatory mediators including histamine, leukotrienes, and prostaglandins that cause vasodilation, increased vascular permeability, bronchoconstriction, and cardiac depression. Epinephrine's alpha-1 agonist activity causes vasoconstriction and reduces vascular permeability, while beta-1 stimulation increases cardiac contractility and heart rate. Beta-2 receptor activation produces bronchodilation and inhibits further mediator release from mast cells and basophils.
Early recognition and immediate epinephrine administration is critical because anaphylactic shock can progress rapidly from initial symptoms to cardiovascular collapse within 10-15 minutes. The intramuscular route (vastus lateralis) is preferred over subcutaneous administration due to more reliable absorption during shock states with poor peripheral perfusion. Epinephrine should be given at the first sign of systemic allergic reaction rather than waiting for full anaphylactic criteria, as the risk-benefit ratio strongly favors early intervention over delayed treatment in suspected cases.